Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Prostate Cancer Research Today


View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications

Volume 2 (2005), Issue 4 (April)

  1. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia.
    Cancer Res, 65(7): 2947-55. [Abstract] [Full-text]
  2. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
    Cancer Res, 65(7): 2872-81. [Abstract] [Full-text]
  3. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Cancer Res, 65(7): 2846-53. [Abstract] [Full-text]
  4. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Cancer Res, 65(7): 2825-31. [Abstract] [Full-text]
  5. Linkage and microarray analyses of susceptibility genes in ACI/Seg rats: a model for prostate cancers in the aged.
    Cancer Res, 65(7): 2610-6. [Abstract] [Full-text]
  6. c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway.
    J Biol Chem, 280(14): 14325-30. [Abstract] [Full-text]
  7. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
    Toxicol Pathol, 33(3): 386-97. [Abstract] [Full-text]
  8. Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors.
    Arch Androl, 51(2): 135-9. [Abstract] [Full-text]
  9. Nonparametric tests of association of multiple genes with human disease.
    Am J Hum Genet, 76(5): 780-93. [Abstract] [Full-text]
  10. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
    Eur J Cancer, 41(6): 954-64. [Abstract] [Full-text]
  11. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Eur J Cancer, 41(6): 941-53. [Abstract] [Full-text]
  12. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.
    Eur J Cancer, 41(6): 932-40. [Abstract] [Full-text]
  13. Quality of life in prostate cancer.
    Eur J Cancer, 41(6): 922-31. [Abstract] [Full-text]
  14. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Eur J Cancer, 41(6): 908-21. [Abstract] [Full-text]
  15. Surgical management of prostate cancer: advances based on a rational approach to the data.
    Eur J Cancer, 41(6): 888-907. [Abstract] [Full-text]
  16. Molecular markers of prostate cancer outcome.
    Eur J Cancer, 41(6): 858-87. [Abstract] [Full-text]
  17. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate.
    Eur J Cancer, 41(6): 846-57. [Abstract] [Full-text]
  18. Changing demography of prostate cancer in Asia.
    Eur J Cancer, 41(6): 834-45. [Abstract] [Full-text]
  19. Screening for prostate cancer.
    Eur J Cancer, 41(6): 825-33. [Abstract] [Full-text]
  20. Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases.
    Dis Colon Rectum, 48(2): 384-9. [Abstract] [Full-text]
  21. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    DNA Cell Biol, 24(4): 264-9. [Abstract] [Full-text]
  22. Micturition Syncope due to paraprostatic pheochromocytoma.
    Urol Int, 74(3): 276-7. [Abstract] [Full-text]
  23. Surgical outcome of radical retropubic prostatectomy is not adversely affected by preexisting three-piece inflatable penile implant.
    Urol Int, 74(3): 221-3. [Abstract] [Full-text]
  24. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
    Urol Int, 74(3): 214-20. [Abstract] [Full-text]
  25. Local anesthesia reduces pain associated with transrectal prostatic biopsy. A prospective randomized study.
    Urol Int, 74(3): 209-13. [Abstract] [Full-text]
  26. Optimization of prostatic biopsy: a prospective randomized trial comparing the sextant biopsy with a 10-core biopsy. Impact of prostatic region of sampling.
    Urol Int, 74(3): 203-8. [Abstract] [Full-text]
  27. Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer suspects.
    Urol Int, 74(3): 198-202. [Abstract] [Full-text]
  28. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    J Natl Cancer Inst, 97(7): 525-32. [Abstract] [Full-text]
  29. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
    Proc Natl Acad Sci U S A, 102(14): 5156-61. [Abstract] [Full-text]
  30. Prostate stem cell antigen is overexpressed in prostate cancer metastases.
    Clin Cancer Res, 11(7): 2591-6. [Abstract] [Full-text]
  31. Infrared spectroscopic imaging for histopathologic recognition.
    Nat Biotechnol, 23(4): 469-74. [Abstract] [Full-text]
  32. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Oncogene, 24(15): 2474-82. [Abstract] [Full-text]
  33. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
    Gene Ther, 12(8): 702-14. [Abstract] [Full-text]
  34. Differential effects of all-trans-retinoic acid (RA) on Erk1/2 phosphorylation and cAMP accumulation in normal and malignant human prostate epithelial cells: Erk1/2 inhibition restores RA-induced decrease of cell growth in malignant prostate cells.
    Eur J Endocrinol, 152(4): 663-9. [Abstract] [Full-text]
  35. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Int J Radiat Oncol Biol Phys, 61(5): 1306-16. [Abstract] [Full-text]
  36. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 61(5): 1299-305. [Abstract] [Full-text]
  37. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Int J Radiat Oncol Biol Phys, 61(5): 1291-8. [Abstract] [Full-text]
  38. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    Int J Radiat Oncol Biol Phys, 61(5): 1285-90. [Abstract] [Full-text]
  39. Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
    Cancer Sci, 96(4): 221-6. [Abstract] [Full-text]
  40. 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7.
    J Biol Chem, 280(15): 14773-9. [Abstract] [Full-text]
  41. Genetic variants in the vitamin D receptor gene and prostate cancer risk.
    Cancer Epidemiol Biomarkers Prev, 14(4): 997-9. [Abstract] [Full-text]
  42. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
    Cancer Epidemiol Biomarkers Prev, 14(4): 993-6. [Abstract] [Full-text]
  43. Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial.
    Cancer Epidemiol Biomarkers Prev, 14(4): 988-92. [Abstract] [Full-text]
  44. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
    Cancer Epidemiol Biomarkers Prev, 14(4): 949-57. [Abstract] [Full-text]
  45. Dietary folate and risk of prostate cancer in Italy.
    Cancer Epidemiol Biomarkers Prev, 14(4): 944-8. [Abstract] [Full-text]
  46. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
    Med Hypotheses, 64(6): 1170-2. [Abstract] [Full-text]
  47. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer.
    Mol Cancer Ther, 4(4): 505-15. [Abstract] [Full-text]
  48. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Eur Urol, 47(5): 695-702. [Abstract] [Full-text]
  49. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
    Eur Urol, 47(5): 587-92. [Abstract] [Full-text]
  50. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study.
    Eur Urol, 47(5): 582-6. [Abstract] [Full-text]
  51. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Eur Urol, 47(5): 575-80; discussion 580-1. [Abstract] [Full-text]
  52. Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol.
    Eur Urol, 47(5): 569-74. [Abstract] [Full-text]
  53. Two Black men with prostate cancer: a narrative approach.
    Br J Health Psychol, 10: 71-84. [Abstract] [Full-text]
  54. Cryosurgical ablation of the prostate: high risk patient outcomes.
    Cancer, 103(8): 1625-30. [Abstract] [Full-text]
  55. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
    Cancer, 103(8): 1615-24. [Abstract] [Full-text]
  56. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Int J Cancer, 115(3): 484-92. [Abstract] [Full-text]
  57. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.
    Nature, 434(7035): 921-6. [Abstract] [Full-text]
  58. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer.
    Cancer Detect Prev, 29(2): 170-4. [Abstract] [Full-text]
  59. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion.
    Cancer Detect Prev, 29(2): 161-9. [Abstract] [Full-text]
  60. Adenosquamous carcinoma of the prostate.
    Int J Urol, 12(3): 319-21. [Abstract] [Full-text]
  61. Intussusception of the bladder neck does not promote early restoration to urinary continence after non-nerve-sparing radical retropubic prostatectomy.
    Int J Urol, 12(3): 275-9. [Abstract] [Full-text]
  62. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Int J Urol, 12(3): 270-4. [Abstract] [Full-text]
  63. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    J Med Chem, 48(8): 2972-84. [Abstract] [Full-text]
  64. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.
    Cancer Res, 65(8): 3447-53. [Abstract] [Full-text]
  65. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
    Cancer Res, 65(8): 3404-9. [Abstract] [Full-text]
  66. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Cancer Res, 65(8): 3328-35. [Abstract] [Full-text]
  67. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
    Cancer Res, 65(8): 3108-16. [Abstract] [Full-text]
  68. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.
    Cancer Res, 65(8): 3081-91. [Abstract] [Full-text]
  69. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.
    Cancer Res, 65(8): 3030-4. [Abstract] [Full-text]
  70. Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancer.
    Cancer Res, 65(8): 2990-2. [Abstract] [Full-text]
  71. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    J Clin Oncol, 23(12): 2789-96. [Abstract] [Full-text]
  72. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
    J Clin Oncol, 23(12): 2772-80. [Abstract] [Full-text]
  73. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Clin Cancer Res, 11(8): 3065-74. [Abstract] [Full-text]
  74. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
    Clin Cancer Res, 11(8): 2883-8. [Abstract] [Full-text]
  75. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
    Vaccine, 23(24): 3114-22. [Abstract] [Full-text]
  76. The continuing role of fine-needle aspiration of the prostate gland into the 21st century: a tribute to Torsten Löwhagen.
    Diagn Cytopathol, 32(5): 315-20. [Abstract] [Full-text]
  77. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
    J Exp Med, 201(8): 1257-68. [Abstract] [Full-text]
  78. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
    Cancer Immunol Immunother, 54(6): 571-6. [Abstract] [Full-text]
  79. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis.
    Thromb Haemost, 93(4): 770-8. [Abstract] [Full-text]
  80. Is prostate-specific membrane antigen a multifunctional protein?
    Am J Physiol Cell Physiol, 288(5): C975-81. [Abstract] [Full-text]
  81. Angiotropism of human prostate cancer cells: implications for extravascular migratory metastasis.
    BJU Int, 95(7): 1099-103. [Abstract] [Full-text]
  82. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?
    BJU Int, 95(7): 969-71. [Abstract] [Full-text]
  83. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
    BJU Int, 95(7): 963-8. [Abstract] [Full-text]
  84. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    BJU Int, 95(7): 961-2. [Abstract] [Full-text]
  85. Early outcomes of active surveillance for localized prostate cancer.
    BJU Int, 95(7): 956-60. [Abstract] [Full-text]
  86. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
    BJU Int, 95(7): 951-5. [Abstract] [Full-text]
  87. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.
    J Clin Invest, 115(4): 959-68. [Abstract] [Full-text]
  88. Detection and correction of patient movement in prostate brachytherapy seed reconstruction.
    Phys Med Biol, 50(9): 2071-87. [Abstract] [Full-text]
  89. Portrayals of treatment decision-making on popular breast and prostate cancer web sites.
    Eur J Cancer Care (Engl), 14(2): 171-4. [Abstract] [Full-text]
  90. Endocrine approaches in the therapy of prostate carcinoma.
    Hum Reprod Update, 11(3): 309-17. [Abstract] [Full-text]
  91. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.
    Br J Cancer, 92(8): 1538-44. [Abstract] [Full-text]
  92. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer.
    J Clin Epidemiol, 58(5): 466-74. [Abstract] [Full-text]
  93. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
    Transplant Proc, 37(2): 958-9. [Abstract] [Full-text]
  94. Marriage and ethnicity predict treatment in localized prostate carcinoma.
    Cancer, 103(9): 1819-25. [Abstract] [Full-text]
  95. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
    Cancer, 103(9): 1833-42. [Abstract] [Full-text]
  96. Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy.
    Cancer, 103(9): 1826-32. [Abstract] [Full-text]
  97. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Int J Cancer, 115(4): 630-40. [Abstract] [Full-text]
  98. Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer.
    Eval Health Prof, 28(2): 142-59. [Abstract] [Full-text]
  99. Modulation of radiation response by histone deacetylase inhibition.
    Int J Radiat Oncol Biol Phys, 62(1): 223-9. [Abstract] [Full-text]
  100. High-dose regions versus likelihood of cure after prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 62(1): 170-4. [Abstract] [Full-text]
  101. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
    Int J Radiat Oncol Biol Phys, 62(1): 164-9. [Abstract] [Full-text]
  102. An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer.
    Int J Radiat Oncol Biol Phys, 62(1): 154-63. [Abstract] [Full-text]
  103. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 62(1): 148-53. [Abstract] [Full-text]
  104. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.
    Int J Radiat Oncol Biol Phys, 62(1): 3-19. [Abstract] [Full-text]
  105. Men's experiences of physical exams and cancer screening tests: a qualitative study.
    Prev Med, 40(6): 628-35. [Abstract] [Full-text]
  106. 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids.
    Prostaglandins Leukot Essent Fatty Acids, 72(5): 363-72. [Abstract] [Full-text]
  107. Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells.
    Arch Biochem Biophys, 437(2): 151-8. [Abstract] [Full-text]
  108. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T.
    Magn Reson Med, 53(5): 1033-9. [Abstract] [Full-text]
  109. In vivo prostate magnetic resonance spectroscopic imaging using two-dimensional J-resolved PRESS at 3 T.
    Magn Reson Med, 53(5): 1177-82. [Abstract] [Full-text]
  110. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination.
    Vaccine, 23(27): 3565-71. [Abstract] [Full-text]
  111. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
    Proc Natl Acad Sci U S A, 102(17): 6201-6. [Abstract] [Full-text]
  112. Fluorocholine PET/CT in patients with prostate cancer: initial experience.
    Radiology, 235(2): 623-8. [Abstract] [Full-text]
  113. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
    J Pain Symptom Manage, 29(4): 352-7. [Abstract] [Full-text]
  114. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
    J Clin Oncol, 23(13): 2918-25. [Abstract] [Full-text]
  115. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    J Clin Oncol, 23(13): 2911-7. [Abstract] [Full-text]
  116. Genetic changes in localized prostate cancer of Japanese patients shown by comparative genomic hybridization.
    Cancer Genet Cytogenet, 159(1): 84-8. [Abstract] [Full-text]
  117. Molecular characterization of a consistent 4.5-megabase deletion at 4q28 in prostate cancer cells.
    Cancer Genet Cytogenet, 159(1): 18-26. [Abstract] [Full-text]
  118. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    J Steroid Biochem Mol Biol, 93(2): 191-200. [Abstract] [Full-text]
  119. Calcidiol and prostate cancer.
    J Steroid Biochem Mol Biol, 93(2): 183-90. [Abstract] [Full-text]
  120. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells.
    J Steroid Biochem Mol Biol, 93(2): 167-72. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.

Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)

Prostate Cancer Books

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)